Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 8/20 | 0.49 |
| ▸ | CTSS | P25774 | 7/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL33528044 | 1.00 | CTSK (0.49) | CTSKCTSSCTSLCTSBFOLH1 | |
| SCHEMBL10161266 | 0.90 | CTSK (0.48) | CTSKCTSSCTSLCTSBFOLH1 | |
| SCHEMBL3386088 | 0.90 | CTSK (0.48) | CTSKCTSSCTSLCTSBFOLH1 | |
| SCHEMBL425834 | 0.90 | CTSK (0.48) | CTSKCTSSCTSLCTSBFOLH1 | |
| SCHEMBL21724288 | 0.89 | CTSK (0.47) | CTSKCTSSCTSLCTSBFOLH1 | |
| SCHEMBL21724289 | 0.89 | CTSK (0.47) | CTSKCTSSCTSLCTSBFOLH1 | |
| SCHEMBL23404059 | 0.89 | REN (0.47) | CTSKCTSSCTSLCTSBMEN1 | |
| SCHEMBL21724476 | 0.89 | REN (0.47) | CTSKCTSSCTSLCTSBMEN1 | |
| SCHEMBL29576469 | 0.89 | REN (0.47) | CTSKCTSSCTSLCTSBMEN1 | |
| SCHEMBL8215506 | 0.88 | CTSS (0.51) | CTSKCTSSCTSLCTSBFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091083-A1 | CYCLIC PROSAPOSIN PEPTIDES AND USES THEREOF | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2026-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091083-A1 | CYCLIC PROSAPOSIN PEPTIDES AND USES THEREOF | PSAP, VIP, IAPP | CTSK 32/4885CTSS 725/4885CTSL 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.